MX2020010999A - Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. - Google Patents

Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.

Info

Publication number
MX2020010999A
MX2020010999A MX2020010999A MX2020010999A MX2020010999A MX 2020010999 A MX2020010999 A MX 2020010999A MX 2020010999 A MX2020010999 A MX 2020010999A MX 2020010999 A MX2020010999 A MX 2020010999A MX 2020010999 A MX2020010999 A MX 2020010999A
Authority
MX
Mexico
Prior art keywords
modifying enzymes
compositions
modulators
methyl modifying
methyl
Prior art date
Application number
MX2020010999A
Other languages
English (en)
Inventor
Victor S Gehling
Ludivine Moine
Alexandre Côté
Avinash Khanna
Jacob I Stuckey
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of MX2020010999A publication Critical patent/MX2020010999A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan nuevos compuestos de Fórmula (I):(ver formula I); y sales farmacéuticamente aceptables de estos, que son útiles para tratar una variedad de enfermedades, trastornos o afecciones asociadas con enzimas modificadoras de metilo. También se proporcionan composiciones farmacéuticas que comprenden los nuevos compuestos de Fórmula (I), sales farmacéuticamente aceptables de estos y métodos para su uso en el tratamiento de una o más enfermedades, trastornos o afecciones, asociados con enzimas modificadoras de metilo.
MX2020010999A 2018-04-18 2019-04-17 Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. MX2020010999A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862659408P 2018-04-18 2018-04-18
PCT/US2019/027932 WO2019204490A1 (en) 2018-04-18 2019-04-17 Modulators of methyl modifying enzymes, compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX2020010999A true MX2020010999A (es) 2021-01-20

Family

ID=66429588

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010999A MX2020010999A (es) 2018-04-18 2019-04-17 Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.

Country Status (22)

Country Link
US (3) US10689371B2 (es)
EP (1) EP3781561B1 (es)
JP (2) JP7256823B2 (es)
KR (1) KR20210003160A (es)
CN (1) CN111989325A (es)
AR (1) AR114793A1 (es)
AU (1) AU2019255310B2 (es)
BR (1) BR112020021194A2 (es)
CA (1) CA3098428A1 (es)
CL (1) CL2020002698A1 (es)
CO (1) CO2020014217A2 (es)
CR (1) CR20200553A (es)
EA (1) EA202092490A1 (es)
IL (1) IL278013B2 (es)
MA (1) MA52288A (es)
MX (1) MX2020010999A (es)
PE (1) PE20201448A1 (es)
PH (1) PH12020551578A1 (es)
SG (1) SG11202009438UA (es)
TW (1) TWI828677B (es)
UA (1) UA127357C2 (es)
WO (1) WO2019204490A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA127357C2 (uk) 2018-04-18 2023-07-26 Констеллатіон Фармацеутікалс, Інк. Модулятори метилмодифікуючих ферментів, композиції та їх використання
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
PE20220562A1 (es) * 2019-07-24 2022-04-13 Constellation Pharmaceuticals Inc Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida
AU2020316072A1 (en) * 2019-07-24 2022-02-24 Constellation Pharmaceuticals, Inc. EZH2 inhibition in combination therapies for the treatment of cancers
TW202144341A (zh) * 2020-03-13 2021-12-01 大陸商四川海思科製藥有限公司 Zeste同源基因增強子2抑制劑及其用途
CN116018335A (zh) * 2020-07-08 2023-04-25 第一三共株式会社 用于制备1,3-苯并二氧杂环戊烯衍生物的方法
IL303025A (en) * 2020-11-18 2023-07-01 Constellation Pharmaceuticals Inc EZH2 inhibition therapies for prostate cancer with androgen receptor mutation
KR20220101295A (ko) 2021-01-11 2022-07-19 주식회사 엘지에너지솔루션 전극 슬러리의 유량 제어가 가능한 전극 슬러리 코팅 시스템 및 이를 이용한 전극 슬러리 코팅 방법
KR20230110210A (ko) * 2022-01-14 2023-07-21 동화약품주식회사 1,3-벤조다이옥솔 유도체 화합물 및 이를 포함하는 약학적 조성물
CN116496263A (zh) * 2022-01-27 2023-07-28 江苏天士力帝益药业有限公司 Ezh1/2抑制剂及其制备和抗肿瘤治疗中的应用
WO2023217018A1 (zh) * 2022-05-07 2023-11-16 贝达药业股份有限公司 Ezh2抑制剂及其在医药上的应用
WO2023244917A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
WO2024038115A1 (en) 2022-08-17 2024-02-22 Morphosys Ag Therapy comprising anti-cd19 antibody and ezh2 modulators

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6317850A (ja) 1986-07-11 1988-01-25 Fuji Photo Film Co Ltd ３−フエノキシカテコ−ル類の製造方法
IL92544A0 (en) 1988-12-08 1990-08-31 Duphar Int Res Piperazine derivatives,their preparation and pharmaceutical compositions containing them
JPH02255674A (ja) 1989-03-27 1990-10-16 Fuji Photo Film Co Ltd ４―アリールオキシ―１，３―ベンゾジオキソール類およびその製造方法
JPH02255673A (ja) 1989-03-27 1990-10-16 Fuji Photo Film Co Ltd ４―アリールオキシー１，３―ベンゾジオキソール類およびその製造方法
JPH02269352A (ja) 1989-04-10 1990-11-02 Fuji Photo Film Co Ltd 感光材料
JP2537682B2 (ja) 1989-04-21 1996-09-25 富士写真フイルム株式会社 ３―アリ―ルオキシカテコ―ル類の製造方法
US5296497A (en) 1989-05-16 1994-03-22 Duphar International Research B.V. 3,4-dehydropiperidine derivatives having psychotropic activity
JPH03130280A (ja) 1989-10-17 1991-06-04 Fuji Photo Film Co Ltd ４―アリールオキシ―１，３―ベンゾジオキソール類の製造方法
JP2816492B2 (ja) 1990-05-23 1998-10-27 コニカ株式会社 ハロゲン化銀写真感光材料
JPH0446175A (ja) 1990-06-14 1992-02-17 Fuji Photo Film Co Ltd ５―ヒドロキシ―３，４―メチレンジオキシ安息香酸誘導体の製造法
JPH0641038A (ja) 1992-07-17 1994-02-15 Mitsubishi Kasei Corp カルボン酸誘導体
DE4326151A1 (de) 1993-08-04 1995-02-09 Hoechst Ag Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
US5629200A (en) 1993-11-18 1997-05-13 Daicel Chemical Industries, Ltd. Production of optically active 2-amino-1-phenylethanol derivatives by asymetrical assimilation
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
DE69739970D1 (de) 1996-01-29 2010-10-07 Univ California Methode zur behandlung sexueller fehlfunktionen
US5968929A (en) 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
JPH10287654A (ja) 1997-04-11 1998-10-27 Nissan Chem Ind Ltd ピラゾロン誘導体及び除草剤
WO1999021422A1 (en) 1997-10-27 1999-05-06 Cortex Pharmaceuticals, Inc. Treatment of schizophrenia with ampakines and neuroleptics
DK1117659T3 (da) 1998-09-29 2004-03-22 Wyeth Corp Substituerede 3-cyanoquinoliner som hæmmere af proteintyrosinkinaser
EP1384713B1 (en) * 1998-12-23 2008-10-15 SmithKline Beecham Corporation 4-amino-azepan-3-one derivatives as protease inhibitors
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
EP1313727A1 (en) 2000-08-21 2003-05-28 AstraZeneca AB Quinazoline derivatives
AU2001281246A1 (en) 2000-08-23 2002-03-04 The Procter And Gamble Company Benzimidazoles and analogues and their use as neutrophil inhibitors
ES2536449T3 (es) 2000-08-24 2015-05-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Derivados de tioflavina para uso en diagnosis de la enfermedad de Alzheimer
AUPR255401A0 (en) 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
EP1368024A4 (en) 2001-03-16 2009-03-18 Novogen Res Pty Ltd TREATMENT OF RESTENOSIS
ES2278016T3 (es) 2001-04-09 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r).
US7141577B2 (en) 2001-04-19 2006-11-28 Astrazeneca Ab Quinazoline derivatives
DE10148618B4 (de) 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148617A1 (de) 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AUPR846401A0 (en) 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
AU2002367023A1 (en) 2001-12-21 2003-07-30 Cytokinetics, Inc. Compositions and methods for treating heart failure
WO2003059898A2 (en) 2002-01-08 2003-07-24 Eisai Co. Ltd. Eponemycin and epoxomicin analogs and uses thereof
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
JP2005528391A (ja) 2002-04-09 2005-09-22 ノボゲン リサーチ ピーティーワイ リミテッド イソフラブ−３−エン及びイソフラバン構造を含む治療方法及び組成物
DE10219294A1 (de) 2002-04-25 2003-11-13 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
WO2004013120A1 (en) 2002-07-29 2004-02-12 F. Hoffmann-La Roche Ag Novel benzodioxoles
AU2002951271A0 (en) 2002-09-06 2002-09-19 Novogen Research Pty Ltd Repair of dna mutagenic damage
US20060153782A1 (en) 2002-09-23 2006-07-13 Novogen Research Pty Ltd Skin photoageing and actinic damage treatment
WO2005011686A1 (en) 2003-07-28 2005-02-10 Applied Research Systems Ars Holding N.V. 2-imino-4-(thio) oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors
KR101153335B1 (ko) 2003-09-24 2012-07-05 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
CN1902213B (zh) 2003-11-18 2010-06-23 诺沃根研究股份有限公司 异黄酮类前药、其组合物和涉及它们的治疗方法
JP2007525485A (ja) 2003-11-19 2007-09-06 ノボゲン リサーチ ピーティーワイ リミテッド 複合的な放射線治療及び化学治療の組成物及び方法
RU2006127414A (ru) 2004-01-16 2008-02-27 Вайет (Us) Хинолиновые промежуточные соединения ингибиторов рецептора тирозинкиназы и их синтез
MXPA06011540A (es) 2004-04-07 2007-01-26 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
US20050245529A1 (en) 2004-04-14 2005-11-03 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
WO2005112932A2 (en) 2004-05-07 2005-12-01 Exelixis, Inc. Raf modulators and methods of use
EP1753428A4 (en) 2004-05-14 2010-09-15 Abbott Lab INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
ITMI20041347A1 (it) 2004-07-05 2004-10-05 Italfarmaco Spa Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
JP2008515955A (ja) 2004-10-12 2008-05-15 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 貧血の治療のためのＰＩ３キナーゼγ阻害剤
SE0402635D0 (sv) 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
JP2006145294A (ja) 2004-11-17 2006-06-08 Univ Nagoya 蛍光標識を行うラベル化試薬、リガンドを表面にもつ基材の製造方法及びラベル化試薬を用いた測定方法
US7524870B2 (en) 2004-12-03 2009-04-28 Hoffmann-La Roche Inc. Biaryloxymethylarenecarboxylic acids as glycogen synthase activators
EP1859793B1 (en) 2005-02-28 2011-04-20 Eisai R&D Management Co., Ltd. Novel combinational use of a sulfonamide compound in the treatment of cancer
US20060223846A1 (en) 2005-03-08 2006-10-05 Dyatkin Alexey B Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
EP1893605A2 (en) 2005-03-31 2008-03-05 AstraZeneca AB Saminopyrimidine derivates with tie2 inhibiting activity
WO2006110447A2 (en) 2005-04-08 2006-10-19 Bayer Pharmaceuticals Corporation Pyrimidine derivatives and their use in the treatment of cancer
DK1881823T3 (en) 2005-05-17 2015-03-02 Sarcode Bioscience Inc COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS
EP1883621A2 (en) 2005-05-25 2008-02-06 Wyeth Methods of preparing 3-cyano-quinolines and intermediates made thereby
JPWO2006129609A1 (ja) 2005-05-30 2009-01-08 塩野義製薬株式会社 ２−ナフチルイミノ−５，５−ジ置換−１，３−チアジン誘導体
MX2007015002A (es) 2005-06-02 2008-02-15 Bayer Cropscience Ag Derivados de heteroarilo sustituidos con fenilalquilo.
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
JP5258561B2 (ja) 2005-07-15 2013-08-07 アルバニー モレキュラー リサーチ， インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
CA2616224A1 (en) 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
CN101277700B (zh) 2005-08-04 2013-02-20 詹森药业有限公司 作为5-羟色胺受体调节剂的嘧啶化合物
JPWO2007020936A1 (ja) 2005-08-17 2009-02-26 第一三共株式会社 抗真菌作用二環性複素環化合物
WO2007081630A2 (en) 2005-12-21 2007-07-19 Janssen Pharmaceutica, N.V. Substituted pyrimidinyl kinase inhibitors
CN101007798B (zh) 2006-01-24 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 苯并间二氧杂环戊烯衍生物及其制备方法和医药用途
WO2007107758A1 (en) 2006-03-23 2007-09-27 Prolysis Ltd Antibacterial agents
AU2007267175A1 (en) 2006-05-30 2007-12-06 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use
WO2008027648A2 (en) 2006-06-26 2008-03-06 Case Western Reserve University Methods and compositions for treating pathologies associated with bdnf signaling
WO2008029168A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
WO2008052256A1 (en) 2006-10-30 2008-05-08 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
RU2333211C1 (ru) 2006-11-01 2008-09-10 Институт физиологически активных веществ Российской Академии наук N,n`-замещенные 3, 7-диазабицикло[3.3.1]нонаны, обладающие фармакологической активностью, фармацевтические композиции на их основе и способ их применения
CA2685860A1 (en) 2007-05-10 2008-11-20 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
BRPI0704074B8 (pt) 2007-08-29 2021-05-25 Univ Estadual Paulista Julio De Mesquita Filho Unesp derivados piperidínicos da (-)-cassina e (-)-spectalina, composições farmacêuticas contendo os mesmos e processos para sua preparação
MX2010004281A (es) 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
WO2009136995A2 (en) 2008-04-16 2009-11-12 Portola Pharmaceuticals, Inc. Inhibitors of syk protein kinase
ES2414159T3 (es) 2008-06-23 2013-07-18 Janssen Pharmaceutica, N.V. Antagonistas de acrilamida piperidilo de CCR2
EP2310378A2 (en) 2008-08-14 2011-04-20 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Oxadiazole-2-oxides as antischistosomal agents
JP2010254629A (ja) 2009-04-27 2010-11-11 Bayer Cropscience Ag 光学活性アゾリン誘導体
TW201109327A (en) 2009-05-28 2011-03-16 Otsuka Pharma Co Ltd Heterocyclic compound
CA2767474A1 (en) 2009-07-10 2011-01-13 Vivalis Substituted pyrrolidinone as inhibitors of hepatitis c ns5b polymerase, the pharmaceutical composition thereof and their therapeutic use
RU2417082C2 (ru) 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
WO2011084657A1 (en) 2009-12-17 2011-07-14 The Lubrizol Corporation Lubricating composition containing an aromatic compound
US8653025B2 (en) 2010-01-27 2014-02-18 AB Pharma Ltd. Polyheterocyclic compounds highly potent as HCV inhibitors
CN101851218B (zh) 2010-04-27 2014-10-15 沈阳药科大学 4,5-二取代芳基异硒唑类衍生物及其用途
WO2011156775A2 (en) 2010-06-10 2011-12-15 Afraxis, Inc. 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
JP5746334B2 (ja) 2010-06-16 2015-07-08 シマベイ セラピューティクス， インコーポレーテッド Ｇｐｒ１２０受容体作動薬及びその使用
EP2598512A1 (en) 2010-07-28 2013-06-05 Medizinische Universität Wien Vinylogous chalcone derivatives and their medical use
US9132136B2 (en) 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
WO2012036278A1 (ja) 2010-09-17 2012-03-22 大正製薬株式会社 グリシントランスポーター阻害物質
WO2012045196A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Phosphoglycerate kinase inhibitors
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
WO2013025484A1 (en) 2011-08-12 2013-02-21 Lapchak Paul A Polyphenol analogs to treat ischemia
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
JPWO2013065835A1 (ja) 2011-11-04 2015-04-02 味の素株式会社 糖尿病治療用医薬組成物
AU2013216721B2 (en) * 2012-02-10 2017-09-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2828245A1 (en) 2012-03-21 2015-01-28 Rutgers, The State University of New Jersey Antimicrobial agents
RU2509770C2 (ru) 2012-06-22 2014-03-20 Общество с ограниченной ответственностью "Молекулярные Технологии" Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных
RU2015111206A (ru) 2012-08-30 2016-10-20 Ниппон Синяку Ко., Лтд. Пиридиновое производное и лекарственное средство
JP6465803B2 (ja) 2012-10-22 2019-02-06 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｅｔｐ誘導体
RU2015143526A (ru) 2013-03-13 2017-04-19 Бостон Байомедикал, Инк. Производные 3-(арил или гетероарил)метилениндолин-2-она в качестве ингибиторов киназного пути раковых стволовых клеток для лечения рака
EP2991963B1 (en) 2013-04-30 2021-07-07 Heinrich-Heine-Universität Düsseldorf Inhibitors of nhr2 and/or runx1/eto-tetramerization
KR20150027922A (ko) 2013-09-04 2015-03-13 주식회사 대웅제약 신규한 항진균성 피리디닐하이드라자이드 유도체
EP3056507B1 (en) 2013-09-09 2020-09-23 Youngene Therapeutics Co., Ltd. C-aryl glucoside derivative, preparation method for same, and medical applications thereof
WO2015069110A1 (en) 2013-11-07 2015-05-14 Aapa B.V. Multiple d2 a(nta)gonists/h3 antagonists for treatment of cns-related disorders
DK3121175T3 (da) * 2014-03-17 2020-03-09 Daiichi Sankyo Co Ltd 1,3-benzodioxolderivater som ezh1- og/eller ezh2-hæmmere
PE20161552A1 (es) 2014-06-17 2017-01-11 Pfizer Compuestos de dihidroisoquinolinona sustituida
AU2015313829B2 (en) 2014-09-11 2020-07-23 Piramal Enterprises Limited Fused heterocyclic compounds as GPR120 agonists
WO2016130396A1 (en) * 2015-02-13 2016-08-18 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
BR112018001688B1 (pt) 2015-07-30 2023-05-02 Daiichi Sankyo Company, Limited Uso de um composto
CA3002436A1 (en) * 2015-11-19 2017-05-26 Biao Lu Benzofuran derivative, preparation method thereof and use thereof in medicine
RS60315B1 (sr) 2016-01-13 2020-07-31 Gruenenthal Gmbh Derivati 3-((hetero-)aril)-alkil-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana
BR112018015413A2 (pt) 2016-02-09 2018-12-18 Inventisbio Inc inibidores de indoleamina-2,3-dioxigenase (ido)
US20170355708A1 (en) * 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
CN106727549A (zh) 2016-11-26 2017-05-31 李�荣 一种治疗抑郁症的药物
KR20190105602A (ko) 2017-01-19 2019-09-17 다이이찌 산쿄 가부시키가이샤 Htlv-1 관련 척수증을 치료하는 것에 사용하기 위한 의약 조성물
US11466020B2 (en) 2017-03-17 2022-10-11 Cornell University Compounds and compositions for inhibition and elimination of Zika infection and uses for same
CA3063440A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras
EP3700527A4 (en) 2017-10-25 2021-03-10 Children's Medical Center Corporation PAPD5 INHIBITORS AND THEIR METHODS OF USE
GB201718285D0 (en) 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
JP2021035913A (ja) 2017-12-21 2021-03-04 石原産業株式会社 Ｎ−メトキシアミド化合物又はその塩、及びそれらを含有する農園芸用殺菌剤
US20210177781A9 (en) 2018-01-12 2021-06-17 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
JP2019168611A (ja) 2018-03-23 2019-10-03 株式会社Adeka 光学フィルタ
WO2019191558A1 (en) 2018-03-30 2019-10-03 San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation Methods for mitigating and preventing proteostasis-based injuries
UA127357C2 (uk) 2018-04-18 2023-07-26 Констеллатіон Фармацеутікалс, Інк. Модулятори метилмодифікуючих ферментів, композиції та їх використання

Also Published As

Publication number Publication date
EP3781561B1 (en) 2024-03-13
CO2020014217A2 (es) 2021-03-08
CL2020002698A1 (es) 2021-01-15
IL278013B2 (en) 2024-01-01
IL278013B1 (en) 2023-09-01
JP2023082132A (ja) 2023-06-13
AR114793A1 (es) 2020-10-14
BR112020021194A2 (pt) 2021-03-23
EP3781561A1 (en) 2021-02-24
JP7256823B2 (ja) 2023-04-12
US20200317651A1 (en) 2020-10-08
EA202092490A1 (ru) 2020-12-23
CR20200553A (es) 2021-04-08
UA127357C2 (uk) 2023-07-26
MA52288A (fr) 2021-04-07
TWI828677B (zh) 2024-01-11
US11274095B2 (en) 2022-03-15
WO2019204490A1 (en) 2019-10-24
KR20210003160A (ko) 2021-01-11
JP2021522166A (ja) 2021-08-30
AU2019255310B2 (en) 2022-11-24
US20190322651A1 (en) 2019-10-24
SG11202009438UA (en) 2020-11-27
PH12020551578A1 (en) 2021-09-13
CN111989325A (zh) 2020-11-24
AU2019255310A1 (en) 2020-10-15
PE20201448A1 (es) 2020-12-10
US20240116905A1 (en) 2024-04-11
CA3098428A1 (en) 2019-10-24
TW202003505A (zh) 2020-01-16
US10689371B2 (en) 2020-06-23
IL278013A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
WO2017210545A8 (en) Potassium channel modulators
MX2021009673A (es) Moduladores de ror-gamma.
EP3569601A3 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12020551425A1 (en) Rimegepant for cgrp related disorders
EP4316591A3 (en) Oxysterols and methods of use thereof
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2019000536A (es) Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1.
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
GEP20186938B (en) Indolizine derivatives as phoshoinositide 3-kinases inhibitors
MX2019001322A (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MX2020009062A (es) Piperidinil-3-(ariloxi)propanamidas y propanoatos.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
WO2021079196A3 (en) Mettl3 modulators
MX2021007247A (es) Derivados de rapamicina.